Expensive cancer drugs and just health care

Best Practice and Research: Clinical Gastroenterology

Volumn 28, Issue 2, 2014, Pages 327-337

  Ehni, Hans Jörg ^a  

^a Inst F Ethik Gesch in der Med   (Germany)

Author keywords

Allocation of health care; Cancer drugs; Expensive drugs; Just health; Justice; Orphan drugs

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESEARCH; DRUG COST; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HUMAN; NEOPLASM; PERSONALIZED MEDICINE; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; SOCIAL DETERMINANTS OF HEALTH; SOCIAL JUSTICE; TREND STUDY;

ALLOCATION OF HEALTH CARE; CANCER DRUGS; EXPENSIVE DRUGS; JUST HEALTH; JUSTICE; ORPHAN DRUGS;

ANTINEOPLASTIC AGENTS; DELIVERY OF HEALTH CARE; DRUG COSTS; HEALTH CARE COSTS; HUMANS; INDIVIDUALIZED MEDICINE; ORPHAN DRUG PRODUCTION; RESOURCE ALLOCATION;

EID: 84899885492     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.02.008     Document Type: Review

References (28)

1. N. Mittmann, H. Au, D. Tu, C.J. O'Callaghan, P.K. Isogai, C.S. Karapetis, and J.R. Zalcberg et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer J Natl Cancer Inst 101 2009 1182 1192
2. J. Norum Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis J Chemother 18 2006 532 537
3. R. Sullivan, J. Peppercorn, K. Sikora, J. Zalcberg, N.J. Meropol, and Neal E. Amir et al. Delivering affordable cancer care in high-income countries Lancet Oncol 12 2011 933 980
4. OECD Health at a glance 2013: OECD indicators 2013 OECD: OECD Publishing
5. M. Herper The world most expensive drugs [Internet] 2010 Available from: http://www.forbes.com/2010/02/19/expensive-drugs-cost-business-healthcare-rare- diseases.html
6. D. Hunter Hyper-expensive treatment [Internet] 2011 Available from: http://www.nuffieldbioethics.org/sites/default/files/files/Hyper-expensive- treatments-background-paper.pdf
7. P. Werth A tale of two drugs [Internet] 2013 Available from: http://www.technologyreview.com/featuredstory/520441/a-tale-of-two-drugs/
8. D. Dickenson Me medicine vs. we medicine 2013 Columbia University Press New York
9. L.J. van't Veer, and R. Bernards Enabling personalized cancer medicine through analysis of gene-expression patterns Nature 452 2008 564 570
10. T. Bodenheimer High and rising health care costs. Part 1: seeking an explanation Ann Intern Med 142 2005 847 854
11. A.R. Omran The epidemiologic transition: a theory of the epidemiology of population change 1971 Milbank Q 83 2005 731 757
12. P.B. Bach, L.B. Saltz, and R.E. Witte In cancer care, cost matters [Internet] 2012 Available from: http://www.nytimes.com/2012/10/15/opinion/a- hospital-says-no-to-an-11000-a-month-cancer-drug.html?-r=0
13. M. Angell The truth about the drug companies 2004 Random House New York
14. European Parliament Directorate General for internal policies. Policy department A: economic and scientific policy. Differences in cost and access to pharmaceutical products in the EU [Internet] 2011 Available from: www.europarl.europa.eu/activities/committees/studies.do?language=EN
15. J. Wolff Pharmaceutical cost control [Internet] 2011 Available from: http://www.ucl.ac.uk/european-institute/analysis-publications/analysis/ healthcare/Jo-Wolff.pdf
16. U.S. Department of Commerce International Trade Administration Pharmaceutical price controls in OECD countries [Internet] 2004 Available from: www.ita.doc.gov/drugpricingstudy
17. C. Wareham Expensive life-extending treatments Background paper for the Nuffield Council [Internet] 2013 Available from: http://www.nuffieldbioethics. org/sites/default/files/files/Forward-look-background-paper-on-expensive-life- extending-treatments.pdf
18. N. Daniels Just health 2008 Cambridge University Press Cambridge
19. J. Rawls A theory of justice 1971 Belknap Press of Harvard University Press Cambridge, Mass
20. R. Arneson Equality of opportunity [Internet] 2008 Available from: http://plato.stanford.edu/archives/fall2008/entries/equal-opportunity/
21. T. Schramme A qualified defence of a naturalist theory of health Med Health Care Philos 10 2007 11 17 [discussion 29-32]
22. I. Robeyns The capabilities approach [Internet] 2008 Available from: http://plato.stanford.edu/archives/sum2011/entries/capability-approach
23. Deutscher Ethikrat Medical benefits and costs in healthcare: the normative role of their evaluation [Internet] 2011 Available from: http://www.ethikrat.org/files/der-opinion-medical-benefits.pdf
24. R. Cookson QALYs and the capability approach Health Econ 14 2005 817 829
25. D. Callahan Setting limits 1995 Georgetown University Press Washington, D.C.
26. S. Segall Health, luck, and justice 2009 Princeton University Press Princeton
27. L.M. Fleck Personalized medicine's ragged edge Hastings Cent Rep 40 2010 16 18
28. CSDH Closing the gap in a generation: health equity through action on the social determinants of health Final report of the Commission on Social Determinants of Health 2008 World Health Organization Geneva